Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer...(rly stage breast cancer the Axxent Elect...),Health

Date:9/8/2008

rly stage breast cancer, the Axxent Electronic Brachytherapy System provides the opportunity to reduce the therapy time required from seven weeks (for external radiation therapy) down to five days. As a result, tens of thousands of patients will have greater access to therapy that is delivered more easily and conveniently. This may accelerate patient choice of breast sparing lumpectomy surgery with adjuvant radiation therapy over the alternative of a full mastectomy.

"In breast cancer, we know there are still tens of thousands of women annually who do not comply with their prescribed radiation treatment after lumpectomy or who choose to have a mastectomy instead of pursuing breast conserving therapy. These groups do not receive radiation therapy and represent about half of the eligible early stage breast cancer population," said Michael Klein, president and CEO of Xoft. "The benefits offered by electronic brachytherapy have tremendous potential to make breast cancer treatment available to these numerous patients annually who otherwise would not receive it. This is especially important for patients who may not have access to specialized radiation vaults requiring seven weeks of radiation because of the cost of travel and lodging plus the impact of being absent from jobs and families during extended treatment.

"In fact, studies presented at the ASCO Breast Cancer Symposium this week support prior findings that much of this problem is based on inability to access therapy because of distance, fear, or difficulty with the logistics of getting to traditional radiation centers --likely even exacerbated by social and ethnic disparities. Many of these issues are addressed by Electronic Brachytherapy," added Klein.

About Xoft Inc.

Xoft, founded in 1998, develops Electronic Brachytherapy (eBx) systems based upon miniaturized X-ray tube technology for the practice of radiation oncology in virtually any clinical setting, eliminating the need for heavi
'/>"/>

SOURCE Xoft Inc. Copyright©2008 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
2. BioElectronics Announces Major Clinical Trials
3. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
4. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
5. GSK Does Not Option XL784 for Further Development
6. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
7. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
8. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
9. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
10. ABC News NIGHTLINE Features HIFU with Sonablate(R) 500 as Non Invasive Treatment Option for Prostate Cancer
11. New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option